BRASTER S.A. shares, of the owner of revolutionary technology for breast cancer diagnosis, debut today on Warsaw Stock Exchange (GPW). Earlier company with success performed public offering, which resulted in acquire from investors PLN 39 MM. Braster is 10th company, which debuted on GPW in 2015. At the same time it is 473 company listed on Warsaw Stock Exchange and 39th with transfer its quotations from the NewConnect market.
Almost PLN 39 MM gained from issuance the Company will designate to finance new development strategy, which aim is to launch BRASTER TESTER for direct sale for women in second half 2016. Funds will be used for building technological line, development of final customer version of the device, development of system for automatic interpretation of thermographic tests received form BRASTER TESTER and for finalization of works linked to product launching in to the market.
"The debut of BRASTER S.A. on the main market of the Warsaw Stock Exchange will beyond any doubt remain one of the most important dates in the history of our company. We are very happy to have new shareholders and we will make every effort to build value for them. I would like to thank everyone who contributed to the success of our offering and enabled us to further develop our company and its revolutionary project." – says Marcin Halicki, President of the Board of BRASTER S.A.
BRASTER S.A. moved its listing to the main market of the WSE from NewConnect, where it debuted in 2012. A total of 3,002,291 shares of series A, B, C, and E and 2,600,000 shares from the new issue of series F were admitted to trading on the regulated market.
The development strategy for 2015–2021 introduced changes to the previous business model. BRASTER will provide global telemedical services in the area of breast cancer using the Braster device, the sale of which will begin in the second half of 2016. According to the strategy, the comprehensive product package consisting of the Braster device, subscription, and additional services will be addressed directly to women, and the target is to generate 70% of revenue from the sale of subscriptions and services, while the revenue from sales of the device is to account for approximately 30% of sales.
In line with the strategy, the device will be first available for sale in Poland. In 2017 it will be placed on the British and German markets, and in the following year on the majority of the remaining EU countries’ markets and the American market.